Literature DB >> 16093787

Intracellular signaling in platelets.

Charles S Abrams1.   

Abstract

PURPOSE OF REVIEW: Over the past few years, a large portion of platelet research has focused on intracellular signaling events that contribute to stable platelet adhesion and aggregation. RECENT
FINDINGS: Studies of knockout mice have suggested critical roles for several previously unappreciated signaling molecules including phosphatidylinositol 3-kinase, the exchange factor CalDAG-GEFI, and the small GTPase Rap1b. These proteins may function to remodel the platelet cytoskeleton and thereby regulate both adhesion and aggregation. The abundant cytoskeletal protein talin appears to be a key regulator of the platelet integrin alphaIIbbeta3. Recent evidence suggests that talin binding to the cytoplasmic tail of beta3 promotes integrin oligomerization, thereby increasing the binding avidity the alphaIIbbeta3 complex for fibrinogen.
SUMMARY: The identification of platelet signaling pathways not only has clinical implications for diagnosis, but perhaps more importantly for rationale drug design. Aspirin, dipyridamole (Persantine), and thienopyridines (ticlopidine and clopidogrel) are all examples of agents that specifically target discrete platelet signaling pathways. These drugs have already been proven to be beneficial in the treatment of cardiovascular disease. Novel agents that target newly identified signaling pathways hold promise of greater specificity and efficacy.

Entities:  

Mesh:

Year:  2005        PMID: 16093787     DOI: 10.1097/01.moh.0000176681.18710.e3

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  8 in total

1.  A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration.

Authors:  Peter Schubert; Jonathan N Thon; Geraldine M Walsh; Cindy H I Chen; Edwin D Moore; Dana V Devine; Juergen Kast
Journal:  Transfusion       Date:  2009-05-18       Impact factor: 3.157

2.  Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents.

Authors:  Jorge Magallon; Jianchun Chen; Leroy Rabbani; George Dangas; Jing Yang; James Bussel; Thomas Diacovo
Journal:  Circulation       Date:  2011-01-10       Impact factor: 29.690

3.  Affinity of talin-1 for the β3-integrin cytosolic domain is modulated by its phospholipid bilayer environment.

Authors:  David T Moore; Patrik Nygren; Hyunil Jo; Kathleen Boesze-Battaglia; Joel S Bennett; William F DeGrado
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-30       Impact factor: 11.205

4.  Synergistic activation of phospholipase C-beta3 by Galpha(q) and Gbetagamma describes a simple two-state coincidence detector.

Authors:  Finly Philip; Ganesh Kadamur; Rosa González Silos; Jimmy Woodson; Elliott M Ross
Journal:  Curr Biol       Date:  2010-06-24       Impact factor: 10.834

Review 5.  Humanizing thrombi in mice.

Authors:  Jorge Magallon; Matthew Egalka; Thomas G Diacovo
Journal:  Trends Cardiovasc Med       Date:  2011-01       Impact factor: 6.677

6.  Signaling and cross-talk by C5a and UDP in macrophages selectively use PLCbeta3 to regulate intracellular free calcium.

Authors:  Tamara I A Roach; Robert A Rebres; Iain D C Fraser; Dianne L Decamp; Keng-Mean Lin; Paul C Sternweis; Mel I Simon; William E Seaman
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

7.  Pentamethylquercetin (PMQ) reduces thrombus formation by inhibiting platelet function.

Authors:  Ming-Lu Liang; Xing-Wen Da; Ao-Di He; Guang-Qiang Yao; Wen Xie; Gang Liu; Ji-Zhou Xiang; Zhang-Yin Ming
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

8.  β3 phosphorylation of platelet αIIbβ3 is crucial for stability of arterial thrombus and microparticle formation in vivo.

Authors:  Weiyi Feng; Manojkumar Valiyaveettil; Tejasvi Dudiki; Ganapati H Mahabeleshwar; Patrick Andre; Eugene A Podrez; Tatiana V Byzova
Journal:  Thromb J       Date:  2017-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.